Doença de alzheimer no Distrito Federal e Brasil: reflexos do envelhecimento populacional e da pandemia
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Jan 31, 2024
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Analisar a morbimortalidade relativa à doença de Alzheimer (DA) no Distrito Federal entre 2012 a 2022 com o intuito de avaliar o impacto do envelhecimento populacional e da pandemia de COVID-19 sobre este agravo. Métodos: Consiste em um estudo retrospectivo transversal quantitativo de dados coletados do Departamento de Informática do Sistema Único de Saúde (DATASUS) referentes ao período de 2012 a 2022. Resultados: O DF, seguindo tendência nacional, apresentou aumento progressivo de morbimortalidade por DA entre 2012 e 2019, com redução de casos de 2020 e 2021, seguido por retomada em 2022, sendo o principal grupo de risco as mulheres com mais de 80 anos. Conclusão: A redução de casos observados na pandemia pode estar relacionada a subnotificação, já que a mortalidade de paciente por COVID é aumentada em pacientes com DA. O aumento do número absoluto de idosos, em especial mulheres, relacionado ao aumento da expectativa de vida parece contribuir de forma significativa para aumento de casos, sugerindo amplo impacto no sistema de saúde em um futuro próximo.
##plugins.themes.bootstrap3.article.details##
Como Citar
Nascimento Júnior Ádria M., SousaA. A. de, PedrosaE. M., & SousaD. A. (2024). Doença de alzheimer no Distrito Federal e Brasil: reflexos do envelhecimento populacional e da pandemia. Revista Eletrônica Acervo Saúde, 24(1), e14634. https://doi.org/10.25248/reas.e14634.2024
Seção
Artigos Originais
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. ABUBAKAR MB, et al. Alzheimer’s Disease: An Update and Insights Into Pathophysiology. Frontiers in Aging Neuroscience, 2022; 14.
2. ARAÚJO JM, et al. Defeitos Cognitivos e COVID-19. Sinapse, 2020; 20(2): 17-22.
3. BEAM CR, et al. Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2018; 64(4): 1077-1083.
4. BERNARDES C, et al. Hospital admissions 2000–2014: A retrospective analysis of 288.096 events in patients with dementia. Archives of Gerontology and Geriatrics, 2018; 77: 150-157.
5. BIGONI A, et al. Brazil's health system functionality amidst of the COVID-19 pandemic: An analysis of resilience. The Lancet Regional Health – Americas, 2022; 10: 100222.
6. BORGES KNG, et al. O impacto da pandemia de COVID-19 em indivíduos com doenças crônicas e a sua correlação com o acesso a serviços de saúde. Revista Científica Escolar Estadual de Saúde Pública de Goiás Cândido Santiago, 2020; 6(3).
7. BUCKLEY RF, et al. To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease? American Journal of Epidemiology, 2019; 188(7): 1213-1223.
8. CAO Q, et al. The Prevalence of Dementia: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2020; 73(3): 1157-1166.
9. CHEN S, et al. Analyses of hospitalization in Alzheimer's disease and Parkinson's disease in a tertiary hospital. Frontiers in Public Health, 2023; 11.
10. CODEPLAN (COMPANHIA DE DESENVOLVIMENTO E PLANEJAMENTO DE BRASÍLIA). Pesquisa Distrital por Amostra de Domicílios (PDAD). Brasília, DF: CODEPLAN, 2018.
11. DONG Y e PENG CY. Principled missing data methods for researchers. Springerplus, 2013; 2(1): 222.
12. FETER N, et al. Ethnoracial disparity among patients with dementia during COVID-19 pandemic. Cadernos De Saúde Pública, 2021; 37(9): e00028321.
13. FONSECA BS, et al. Análise da influência dos hormônios sexuais na Doença de Alzheimer: revisão integrativa de literatura. Revista Eletrônica Acervo Saúde, 2021; 13(9): e8815.
14. FRANÇA E, et al. Cause-specific mortality for 249 causes in Brazil and states during 1990–2015: a systematic analysis for the global burden of disease study 2015. Population Health Metrics, 2017; 15(39).
15. IBGE (INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA). Pesquisa nacional por amostra de domicílios contínua: PNAD Contínua. Rio de Janeiro: IBGE, 2019.
16. JAGUST WJ. The changing definition of Alzheimer's disease. The Lancet Neurology, 2021; 20(6): 414- 415.
17. LIMA VSM, et al. Caracterização das internações em Unidade de Terapia Intensiva Adulto do Distrito Federal: uma comparação entre o período pré e durante a pandemia da Covid-19. Revista Eletrônica Acervo Saúde, 2023; 23(2): e11686.
18. LIESI EH, et al. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology, 2013; 80(19): 1778-1783.
19. MEIJER E, et al. Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study. The Lancet Regional Health, 2022; 20: 100445.
20. MOK VCT, et al. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020; 16(11): 1571-1581.
21. NANDI A, et al. Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: A value of statistical life approach. The Lancet eClinical Medicine, 2022; 51: 101580.
22. NICHOLS E, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, 2022; 7(2): e105-e125.
23. PEREIRA WAB, et al. Increase in life expectancy and population growth in Brazil with impact on the number of people living with chronic-degenerative diseases: challenges for the management of Alzheimer’s Disease. Research, Society and Development, 2023; 12(5): e24112531673.
24. RUDNICKA-DROŻAK E, et al. Links between COVID-19 and Alzheimer's Disease-What Do We Already Know? International Journal of Environmental Research and Public Health, 2023; 20(3): 2146.
25. SCHILLING LP, et al. Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dementia & Neuropsychologia, 2022; 16(3): 25–39.
26. SKARIA AP. The economic and societal burden of Alzheimer disease: managed care considerations. The American Journal of Managed Care, 2022; 28(10): S188-S196.
27. WIMO A, et al. The worldwide costs of dementia in 2019. Alzheimer's & Dementia, 2023; 19: 2865-2873.
28. XUE L, et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019. Frontiers in Aging Neuroscience, 2022; 14: 937486.
29. YAN Y, et al. X-linked ubiquitin-specific peptidase 11 increases tauopathy vulnerability in women. Cell, 2022; 185(21): 3913-3930.e19.
30. ZHANG Q, et al. COVID-19 Case Fatality and Alzheimer's Disease. Journal of Alzheimer’s Disease: JAD, 2021; 84(4): 1447-1452.
31. ZHANG XX, et al. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. The Journal of Prevention of Alzheimer's Disease, 2021; 8: 313–321.
2. ARAÚJO JM, et al. Defeitos Cognitivos e COVID-19. Sinapse, 2020; 20(2): 17-22.
3. BEAM CR, et al. Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2018; 64(4): 1077-1083.
4. BERNARDES C, et al. Hospital admissions 2000–2014: A retrospective analysis of 288.096 events in patients with dementia. Archives of Gerontology and Geriatrics, 2018; 77: 150-157.
5. BIGONI A, et al. Brazil's health system functionality amidst of the COVID-19 pandemic: An analysis of resilience. The Lancet Regional Health – Americas, 2022; 10: 100222.
6. BORGES KNG, et al. O impacto da pandemia de COVID-19 em indivíduos com doenças crônicas e a sua correlação com o acesso a serviços de saúde. Revista Científica Escolar Estadual de Saúde Pública de Goiás Cândido Santiago, 2020; 6(3).
7. BUCKLEY RF, et al. To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease? American Journal of Epidemiology, 2019; 188(7): 1213-1223.
8. CAO Q, et al. The Prevalence of Dementia: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2020; 73(3): 1157-1166.
9. CHEN S, et al. Analyses of hospitalization in Alzheimer's disease and Parkinson's disease in a tertiary hospital. Frontiers in Public Health, 2023; 11.
10. CODEPLAN (COMPANHIA DE DESENVOLVIMENTO E PLANEJAMENTO DE BRASÍLIA). Pesquisa Distrital por Amostra de Domicílios (PDAD). Brasília, DF: CODEPLAN, 2018.
11. DONG Y e PENG CY. Principled missing data methods for researchers. Springerplus, 2013; 2(1): 222.
12. FETER N, et al. Ethnoracial disparity among patients with dementia during COVID-19 pandemic. Cadernos De Saúde Pública, 2021; 37(9): e00028321.
13. FONSECA BS, et al. Análise da influência dos hormônios sexuais na Doença de Alzheimer: revisão integrativa de literatura. Revista Eletrônica Acervo Saúde, 2021; 13(9): e8815.
14. FRANÇA E, et al. Cause-specific mortality for 249 causes in Brazil and states during 1990–2015: a systematic analysis for the global burden of disease study 2015. Population Health Metrics, 2017; 15(39).
15. IBGE (INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA). Pesquisa nacional por amostra de domicílios contínua: PNAD Contínua. Rio de Janeiro: IBGE, 2019.
16. JAGUST WJ. The changing definition of Alzheimer's disease. The Lancet Neurology, 2021; 20(6): 414- 415.
17. LIMA VSM, et al. Caracterização das internações em Unidade de Terapia Intensiva Adulto do Distrito Federal: uma comparação entre o período pré e durante a pandemia da Covid-19. Revista Eletrônica Acervo Saúde, 2023; 23(2): e11686.
18. LIESI EH, et al. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology, 2013; 80(19): 1778-1783.
19. MEIJER E, et al. Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study. The Lancet Regional Health, 2022; 20: 100445.
20. MOK VCT, et al. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020; 16(11): 1571-1581.
21. NANDI A, et al. Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: A value of statistical life approach. The Lancet eClinical Medicine, 2022; 51: 101580.
22. NICHOLS E, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, 2022; 7(2): e105-e125.
23. PEREIRA WAB, et al. Increase in life expectancy and population growth in Brazil with impact on the number of people living with chronic-degenerative diseases: challenges for the management of Alzheimer’s Disease. Research, Society and Development, 2023; 12(5): e24112531673.
24. RUDNICKA-DROŻAK E, et al. Links between COVID-19 and Alzheimer's Disease-What Do We Already Know? International Journal of Environmental Research and Public Health, 2023; 20(3): 2146.
25. SCHILLING LP, et al. Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dementia & Neuropsychologia, 2022; 16(3): 25–39.
26. SKARIA AP. The economic and societal burden of Alzheimer disease: managed care considerations. The American Journal of Managed Care, 2022; 28(10): S188-S196.
27. WIMO A, et al. The worldwide costs of dementia in 2019. Alzheimer's & Dementia, 2023; 19: 2865-2873.
28. XUE L, et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019. Frontiers in Aging Neuroscience, 2022; 14: 937486.
29. YAN Y, et al. X-linked ubiquitin-specific peptidase 11 increases tauopathy vulnerability in women. Cell, 2022; 185(21): 3913-3930.e19.
30. ZHANG Q, et al. COVID-19 Case Fatality and Alzheimer's Disease. Journal of Alzheimer’s Disease: JAD, 2021; 84(4): 1447-1452.
31. ZHANG XX, et al. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. The Journal of Prevention of Alzheimer's Disease, 2021; 8: 313–321.